Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia

Ann Hematol. 2022 May;101(5):1137-1139. doi: 10.1007/s00277-021-04688-5. Epub 2021 Oct 6.

Authors

Kelsey Uminski¹, Roy Khalife², Jill Fulcher², Lisa Duffett², Tzu-Fei Wang², Alan Tinmouth²

Affiliations

¹ Division of Hematology, Department of Medicine, University of Ottawa, 501 Smyth Road, Box 201A, Ottawa, ON, K1H 8L6, Canada. keuminski@toh.ca.
² Division of Hematology, Department of Medicine, University of Ottawa, 501 Smyth Road, Box 201A, Ottawa, ON, K1H 8L6, Canada.

PMID: 34611720
DOI: 10.1007/s00277-021-04688-5

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Antimetabolites, Antineoplastic / adverse effects
Factor V Deficiency*
Humans
Mercaptopurine / adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Antimetabolites, Antineoplastic
Mercaptopurine